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Abstract
Background: Patients with diffuse cutaneous systemic sclerosis (dcSSc) have a poor prognosis. The importance of
monitoring subjective measures of functioning and disability, such as the Health Assessment Questionnaire-
Disability Index (HAQ-DI), is important as dcSSc is rated by patients as worse than diabetes or hemodialysis for
quality of life impairment. This European Scleroderma Trials and Research (EUSTAR) database analysis was
undertaken to examine the importance of impaired functionality in dcSSc prognosis. The primary objectives were
to identify predictors of death and HAQ-DI score progression over 1 year. HAQ-DI score, major advanced organ
involvement, and death rate were also used to develop a comprehensive model to predict lifetime dcSSc
progression.
Methods: This was an observational, longitudinal study in patients with dcSSc registered in EUSTAR. Death and
HAQ-DI scores were, respectively, analyzed by Cox regression and linear regression analyses in relation to baseline
covariates. A microsimulation Markov model was developed to estimate/predict natural progression of dcSSc over a
patient’s lifetime.
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Results: The analysis included dcSSc patients with (N = 690) and without (N = 4132) HAQ-DI score assessments from
the EUSTAR database. Baseline HAQ-DI score, corticosteroid treatment, and major advanced organ involvement
were predictive of death on multivariable analysis; a 1-point increase in baseline HAQ-DI score multiplied the risk of
death by 2.7 (p < 0.001) and multiple advanced major organ involvement multiplied the risk of death by 2.8
(p < 0.05). Multivariable analysis showed that baseline modified Rodnan Skin Score (mRSS) and baseline HAQ-DI
score were associated with HAQ-DI score progression at 1 year (p < 0.05), but there was no association between
baseline organ involvement and HAQ-DI score progression at 1 year. HAQ-DI score, major advanced organ
involvement, and death were successfully used to model long-term disease progression in dcSSc.
Conclusions: HAQ-DI score and major advanced organ involvement were comparable predictors of mortality risk in
dcSSc. Baseline mRSS and baseline HAQ-DI score were predictive of HAQ-DI score progression at 1 year, indicating a
correlation between these endpoints in monitoring disease progression. It is hoped that this EUSTAR analysis may
change physician perception about the importance of the HAQ-DI score in dcSSc.
Keywords: EUSTAR registry, Diffuse cutaneous systemic sclerosis, Health Assessment Questionnaire-Disability Index,
HAQ-DI score
Introduction
Systemic sclerosis (SSc) is an autoimmune disorder char-
acterized by extensive fibrosis and vasculopathy that can
affect the skin and internal organs [1]. It imposes a sub-
stantial burden of pain, disfigurement, and impaired
functionality that can markedly reduce health-related
quality of life [2, 3]. SSc is a heterogeneous disease, and
it is commonly subclassified according to the extent of
skin involvement [4]. Patients with diffuse cutaneous
systemic sclerosis (dcSSc) have the poorest prognosis,
with a 10-year mortality rate of at least 50% [5]. It is,
therefore, important to monitor these patients in order
to provide a comprehensive and long-term assessment
of disease progression.
To date, the modified Rodnan Skin Score (mRSS) has
been widely used to monitor progression in clinical stud-
ies; it is a semi-quantitative measure of skin thickness in
different body areas that is used as a proxy for disease
severity, progression, and mortality risk [6, 7]. Short-
term progressive skin fibrosis (i.e., within 1 year mea-
sured via mRSS) is associated with a later decline in lung
function and worse survival in patients with dcSSc [7].
However, the progression of skin fibrosis diverges from
other organ involvement during the disease course. It
often regresses spontaneously once it has reached its
peak, while lung fibrosis continues to progress in most
cases. This can make short-term clinical trials of thera-
peutic agents challenging as outcomes reported with the
mRSS do not always correlate with other objective mea-
sures [8, 9].
Ensuring that the patient voice is heard is also central
to decision making. Patients with SSc have strong views
about the chronic nature and negative consequences of
their disease. They perceive the impact of their disease
on daily living as more severe than patients with diabetes
or those undergoing hemodialysis [10]. However, patient
opinion is often not satisfactorily included in decision
making [2]. Patient-reported outcomes have become in-
creasingly important in recent years; they could address
this imbalance and increase our understanding of the
wider impact of these diseases.
Accumulating evidence suggests that the Health As-
sessment Questionnaire-Disability Index (HAQ-DI) is a
useful measure of functionality in SSc [11–13]. This is a
self-reported questionnaire covering 20 items in eight
domains related to measuring difficulty in performing
activities of daily living: dressing, arising, eating, walking,
hygiene, reach, grip, and common daily activities [12,
13]. Each question is rated on a 0–3 scale, where 0 indi-
cates “without difficulty” and 3 indicates “unable to do,”
and additional points can be added if aids or devices are
needed for specific activities; thus, increasing score indi-
cates worse functionality [12, 13]. HAQ-DI score is a re-
liable measure that is sensitive to change in disease
activity in cross-sectional (patients and physicians) and
longitudinal studies [2, 12]. As a result, it is now increas-
ingly used as an endpoint in clinical studies investigating
treatment outcomes in SSc.
The primary aims of this European Scleroderma Trials
and Research (EUSTAR) database analysis of patients
with dcSSc were (1) to identify predictors of death in-
cluding HAQ-DI score, advanced major organ involve-
ment, and other clinical characteristics; (2) to identify
predictors of HAQ-DI score progression over 1 year; and
(3) to develop a transition model to predict natural pro-
gression of dcSSc over a lifetime using HAQ-DI score,
major advanced organ involvement, and death rates.
Methods
Design and study population
This was an observational, longitudinal study of patients
with dcSSc registered in the EUSTAR database. The
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EUSTAR network has been described elsewhere [14, 15].
In brief, EUSTAR is a growing database of patients with
scleroderma treated at centers worldwide; all patients
undergo annual scheduled clinic visits, providing obser-
vational, longitudinal data.
For this analysis, patient data were extracted from
January 1995 to February 2019. Ethics Committee ap-
proval was obtained from all centers, and informed con-
sent was provided when required by the ethical
regulations at the specific centers. Patients were ≥ 18
years of age and to have SSc as classified by the Ameri-
can College of Rheumatology (ACR) (1980) or ACR/
European League Against Rheumatism criteria (2013)
[16, 17]. Patients with dcSSc were identified from this
cohort based on the LeRoy criteria [4], and those with
the available data for the first non-Raynaud’s
manifestation were extracted. If data on the LeRoy cri-
teria were not available, then the extent of skin involve-
ment (e.g., skin fibrosis at any time with mRSS ≥ 1 of
upper arms, thorax, abdomen, or thighs) was used as a
surrogate.
Population and outcomes
Analyses were performed using patients with dcSSc who
met the above criteria with or without HAQ-DI score as-
sessments. Patients with HAQ-DI score were further di-
vided into either those who had ≥ 1 HAQ-DI or those
who had ≥ 2 HAQ-DI score assessments. Clinical data
used in analyses are shown in Table 1, Fig. 1, and Fig. S1.
Analyses of the impact of organ involvement focused
on the major advanced complications seen in dcSSc pa-
tients. Advanced gastrointestinal (GI) events were
Table 1 Baseline demographic and clinical characteristics according to HAQ-DI score assessments
Parameters dcSSc with no HAQ-DI score
at any time
N = 4132
dcSSc with ≥ 1 HAQ-DI
score
N = 690




Mean (SD) 52.2 (13.6) 53.8 (12.9) 53.1 (12.7)
IQR 42.6–62.4 45.6–62.6 43.9–62.3
Age (years) at onset of RP, N 3953 677 414
Mean (SD) 43.3 (14.7) 42.4 (14.4) 42.5 (14.3)
IQR 32.7–54.0 32.4–52.0 32.1–52.3
Female, n (%) 3214 (77.8%) 537 (77.8%) 320 (75.5%)
Disease duration, n (%)
≤ 18months 962 (23.3%) 60 (8.7%) 39 (9.2%)
> 18 months 3170 (76.7%) 630 (91.3%) 385 (90.8%)
Current digital ulcers, n (%)
Yes 1493 (36.6%) 120 (18.3%) 70 (17.3%)
No 2585 (63.4%) 535 (81.7%) 335 (82.7%)
Puffy fingers, n (%)
Yes 972 (48.7%) 216 (35.5%) 148 (39.1%)
No 1024 (51.3%) 392 (64.5%) 231 (60.9%)
mRSS, N 3895 656 403
Mean (SD) 16.4 (9.9) 11.7 (9.0) 11.8 (8.6)
IQR 9.0–23.0 5.0–17.0 5.0–17.0
HAQ-DI score
Mean (SD) NA 1.0 (0.8) 1.1 (0.8)
IQR NA 0.4–1.6 0.4–1.8
Advanced organ involvement, n (%)
None 3448 (83.7%) 468 (68.8%) 295 (69.9%)
One 585 (14.2%) 178 (26.2%) 108 (25.6%)
Multiple 86 (2.1%) 34 (5.0%) 19 (4.5%)
Missing 13 10 2
dcSSc diffuse cutaneous systemic sclerosis, HAQ-DI Health Assessment Questionnaire-Disability Index, IQR interquartile range, mRSS Modified Rodnan Skin Score,
NA not available, RP Raynaud’s phenomenon, SD standard deviation
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defined as malabsorption or ≥ 10% weight loss from
baseline. Echocardiographic measurement of systolic
pulmonary arterial pressure > 45mmHg was used as a
proxy for pulmonary hypertension (PH) as data on right
heart catheterization were not collected routinely in the
database. Interstitial lung disease (ILD) was confirmed
by high-resolution computed tomography or chest X-
ray, and significant lung involvement was defined as ILD
on imaging and forced vital capacity < 75% predicted.
Cardiac involvement was defined as left ventricular ejec-
tion fraction (LVEF) ≤ 45% measured on echocardiog-
raphy, and renal involvement was defined as the
presence of renal crisis (abrupt onset of severe hyperten-
sion accompanied by rapidly progressive renal failure,
hypertensive encephalopathy, congestive heart failure,
and/or microangiopathic hemolytic anemia).
Patients could be enrolled at any time in the disease
course if they were classified as having SSc (defined as
baseline). Clinical history, demographic characteristics,
use of immunomodulatory treatment, and death were
documented for patients with or without HAQ-DI score
assessments; this information was based on medical
records in the EUSTAR database. It was intended that
patients should be documented once a year. Death was
documented with the date or year (if the date was not
exactly known) and reason of death.
Statistical analyses
Regression analyses to identify predictors of death and
HAQ-DI score progression
Patients with ≥ 2 HAQ-DI score assessments were se-
lected to model prediction of HAQ-DI score at 1 year (i.e.,
progression). Patients with ≥ 2 specific organ assessments
were selected to predict major advanced organ involve-
ment. Using these populations, the relationship between
baseline characteristics and death rates and HAQ-DI score
progression at 1 year were examined both at the univariate
level and in multivariable models. Death rates and HAQ-
DI scores were analyzed by Cox regression and linear re-
gression analyses, respectively, in relation to each baseline
covariate: gender, age at onset of Raynaud’s phenomenon,
RNA polymerase III positive, immunomodulator treat-
ment, corticosteroid use > 10mg/day, HAQ-DI score,
mRSS, and number of major advanced organs involved
(0, 1, or ≥ 2 based on lung, cardiac, GI, PH, or renal in-
volvement). All analyses were performed using IBM® SPSS
statistics 24.0 and R software (version 3.4.4).
Transition model for dcSSc
A microsimulation Markov model was developed to de-
termine the natural progression of dcSSc over a patient’s
lifetime horizon. The Markov model was chosen as it
enables simulation of a patient in different health states
(e.g., various HAQ-DI levels, organ involvement or not,
and alive or dead). Each patient was modelled independ-
ently to allow for the heterogeneity of the dcSSc popula-
tion; it was, therefore, a microsimulation. Within the
abovementioned dataset, three risk equations were de-
veloped to model the evolution of the following end-
points: HAQ-DI score; major advanced organ
involvement; death.
The HAQ-DI score is a continuous variable and was
transformed into a categoric variable in this model to
represent five different health states ([0− 0.5], [0.5− 1.0],
[1.0− 1.5], [1.5− 2.0], and [2.0− 3.0]); the health states
were based on expert opinion and were initially defined
as uniformly splitting the 0− 3 HAQ-DI score range into
six categories (i.e., this is the maximum amount of cat-
egories that enable the multistate modelling [MSM]
package to converge when fitting a transition matrix be-
tween HAQ-DI states); however, the two last categories
did not contain enough patients and were grouped into
a single state, leaving five states in total. The HAQ-DI
transition matrix was calibrated using an MSM that pro-
vides constant transition probabilities over time from
any HAQ-DI state to any other one. For calibration of
Fig. 1 EUSTAR cohort with dcSSc (February 11, 2019). ACR American
College of Rheumatology, ACR/EULAR American College of
Rheumatology/European League Against Rheumatism, dcSSc diffuse
cutaneous systemic sclerosis, EUSTAR European Scleroderma Trials
and Research, HAQ-DI Health Assessment Questionnaire-Disability
Index, RP Raynaud’s phenomenon, SSc systemic sclerosis
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the HAQ-DI transition matrix, transition intensities
were developed using longitudinal, patient-level data for
HAQ-DI states as a function of gender, age at baseline,
and lung status at baseline. A 1-year cycle was chosen to
transform intensities into yearly transition probabilities
of moving between the five HAQ-DI states (Table S1).
For calibration of the organ equations, longitudinal
patient-level data were used to calculate survival in the
no-organ-involved state in relation to specific patient
characteristics at baseline (age, sex, HAQ-DI states, and
major advanced organ involvement such as lung, PH,
cardiac, renal, or GI) (Table S2). This equation was cali-
brated using the survival package (R software).
For calibration of the third equation, death rates were
calculated using a standardized mortality ratio (SMR),
defined as the ratio of observed deaths in the dcSSc
EUSTAR population to expected deaths in the general
population (adjusted for age- and gender-specific rates)
(Fig. 2). Thus, SMRs differ from hazard ratios as these
compare the mortality of specific dcSSc patients with
the mortality of other dcSSc patients. The general popu-
lation mortality data were extracted from the 2014
Italian life tables [18] as Italian was the most prevalent
nationality (22%) in the analyzed cohort from the
EUSTAR database at the time of analysis [19]. This was
used as a mortality multiplier, sensitive to the fact that a
patient is in a specific HAQ-DI state or any advanced
organ state.
After calibration, a microsimulation structure was con-
structed, which enabled patients to move between the
five HAQ-DI states, to develop major advanced organ
involvement, and/or to enter a death state. An illustra-
tive microsimulation was proposed for a patient (simu-
lated over a lifetime horizon) to randomly transition
between the five HAQ-DI states, to develop lung/no
lung involvement, and to enter a death state at each time
cycle. The structure of the model is shown in Fig. 3. In
that structure, a female patient starts in a specific HAQ-
DI and lung state (defined by baseline characteristics).
At the start of each cycle, based on her HAQ-DI state
and lung state in the previous cycle, she could evolve to-
wards another HAQ-DI and/or lung state, or die. The
equations used to model the transitions in that illustra-
tive model were:
Fig. 2 Calculation of SMR using death rates from the EUSTAR dcSSc cohort (observed deaths) and deaths in the general population (expected
deaths from the Italian life tables) in patients with ≥ 1 HAQ-DI score measurement. CI confidence interval, dcSSc diffuse cutaneous systemic
sclerosis, EUSTAR European Scleroderma Trials and Research, GI gastrointestinal, HAQ-DI Health Assessment Questionnaire-Disability Index, PH
pulmonary arterial hypertension, SMR standardized mortality ratio
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 HAQ-DI state in t = f(age in t − 1, sex, lung status in
t − 1)
 Lung status in t = f(HAQ-DI state in t − 1, time
since disease onset)
 Mortality in t = f(lung status in t − 1, age in t − 1, sex)
where t = time (years); f = “is function of”.
Several assumptions were made as these equations
were calibrated on data with different time horizons
(only lung status was a time-dependent predicted vari-
able). The calibrated equations were:
 HAQ-DI state after 1 year = f(age at baseline, sex,
lung status at baseline)
 Lung status in year t = f(HAQ-DI state at baseline,
time since disease onset)
 Mortality in t = f(lung status in t − 1, age in t − 1, sex)
Results
Study population
A total of 4132 dcSSc patients without HAQ-DI score
and 690 dcSSc patients with HAQ-DI score assessments
were included in the EUSTAR registry. Of the 690 pa-
tients, 424 patients (61.4%) had ≥ 2 HAQ-DI score as-
sessments and were included in HAQ-DI score
progression and death rate analyses, and 266 patients
(38.6%) had only one HAQ-DI score assessment and
were included in the death rate analysis (Fig. 1). The
proportion of patients with major advanced organ in-
volvement is shown in Table 1. One advanced organ in-
volvement was reported in 14.2% of patients with no
HAQ-DI score assessments, in 26.2% with ≥ 1 HAQ-DI
score assessment, and in 25.6% with ≥ 2 HAQ-DI score
assessments.
The baseline characteristics of patients with ≥ 1 (N =
690) and ≥ 2 (N = 424) HAQ-DI score assessments are
summarized in Table 1. In general, the demographic
characteristics of these patients were comparable with
those with no HAQ-DI score assessments (N = 4132).
However, most patients with ≥ 1 (77.5%) and ≥ 2 (77.1%)
HAQ-DI score assessments had received immunomodu-
lator treatment, whereas only 32.2% of those with no
HAQ-DI data had received treatment (Fig. S1). For pa-
tients with ≥ 2 HAQ-DI scores, the mean (standard
Fig. 3 Illustration of HAQ-DI transition states (0–0.5, 0.5–1.0, 1.0–1.5, 1.5–2.0, and 2.0–3.0), risk of advanced lung involvement, and death for a
patient with dcSSc. HAQ-DI state in t − 1 influences the lung status in t. Similarly, the lung status in t − 1 influences the HAQ-DI state in t. The
lung status in t − 1 (which is influenced by the HAQ-DI state in t − 2) influences the mortality in t. t = time in years, and f = “is a function of”. Note:
Each HAQ-DI state should be included in a “triangle” as they all influence the lung and no lung states. However, due to lack of space on the
diagram, two triangles were omitted. dcSSc diffuse cutaneous systemic sclerosis, HAQ-DI Health Assessment Questionnaire-Disability Index
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deviation [SD]) duration between first and second as-
sessment of the HAQ-DI score was 11.8 (9.6) months.
Predictors of death
Of the 690 patients with ≥ 1 HAQ-DI score assessment,
522 (75.7%) had follow-up information with a median
duration of 29.9 months (range 2.1–86.2 months), and
41 (7.9%) patients died. Univariate analysis showed that
baseline HAQ-DI score, older age at onset of Raynaud’s
phenomenon, corticosteroid treatment > 10mg/day, and
advanced major organ involvement (other than renal in-
volvement) were respectively associated with the risk of
death (Table 2). Of the baseline HAQ-DI score, all eight
domains were associated with mortality. When testing
the eight domains in a multivariable model with stepwise
backward selection, only the domains walking and dress-
ing remained as predictors of mortality (Table S3).
Multivariable analysis showed that baseline HAQ-DI
score, corticosteroid treatment > 10mg/day, and major
advanced organ involvement (1 or multiple organs)
remained predictive of death after adjustment on base-
line parameters; a 1-point increase in baseline HAQ-DI
score multiplied the risk of death by 2.7 (p < 0.001) and
multiple advanced major organ involvement multiplied
the risk of death by 2.8 (p < 0.05) (Table 3).
Predictors of HAQ-DI score progression
Of patients who had ≥ 2 HAQ-DI score assessments,
HAQ-DI score progression after 1 year (± 2months) was
monitored in 62.3% (n = 264/424); of those, 78.0%
(206/264) also had a HAQ-DI score assessment at 1 year.
The mean (SD) change in HAQ-DI score from baseline
to 1 year was 0.004 (0.39) for all patients (n = 206), 0.02
(0.39) in those with no major advanced organ involve-
ment after 1 year (n = 146), − 0.06 (0.38) in those with
≥ 1 major advanced organ involvement after 1 year
(n = 24/55; 43.6% progressors), and 0.15 (0.27) in those
with ≥ 2 major advanced organs involved (n = 3/5; 60.0%
progressors).
On multivariable analysis (Table 4), patients with high
baseline mRSS scores or esophageal symptoms showed
Table 2 Univariate Cox regression analysis of factors influencing
risk of death in patients with ≥ 1 HAQ-DI measurement
Baseline parameter HR 95% CI for HR p value
Male gender 1.15 0.57, 2.35 0.698
HAQ-DI score 3.01 1.98, 4.60 < 0.001
Age at onset of RP 1.03 1.00, 1.05 0.030
mRSS 1.02 0.99, 1.05 0.303
RNA polymerase III positive 0.04 0.00, 11.11 0.260
Anti-topoisomerase I antibody 0.92 0.45, 1.88 0.817
Immunomodulator treatment 0.86 0.45, 1.63 0.638
Corticosteroids > 10 mg/day 6.29 2.64, 14.98 < 0.001
One advanced organ involvement 3.93 1.99, 7.78 < 0.001
Two advanced organ involvement 8.43 3.40, 20.91 < 0.001
Advanced lung involvement 4.81 2.37, 9.77 < 0.001
Advanced cardiac involvement 6.24 1.47, 26.50 0.013
Advanced GI involvement 2.22 1.06, 4.64 0.035
Advanced PH involvement 6.50 2.66, 15.88 < 0.001
Advanced renal involvement 1.12 0.15, 8.13 0.914
CI confidence interval, GI gastrointestinal, HAQ-DI Health Assessment
Questionnaire-Disability Index, HR hazard ratio, mRSS Modified Rodnan Skin
Score, PH pulmonary arterial hypertension, RP Raynaud’s phenomenon
Table 3 Multivariable Cox regression analysis of factors affecting
risk of death in patients with ≥ 1 HAQ-DI measurement
Baseline parameter HR 95% CI for HR p value
HAQ-DI score 2.69 1.71, 4.23 < 0.001
Age at onset of RP 1.02 0.99, 1.04 0.177
mRSS 1.01 0.98, 1.04 0.527
Male gender 1.06 0.48, 2.35 0.888
Immunomodulator treatment 0.41 0.20, 0.84 0.014
Corticosteroids > 10 mg/day 5.41 2.10, 13.97 < 0.001
Advanced organ involvement (reference: no organ involvement)
One 3.57 1.77, 7.18 < 0.001
Multiple 4.81 1.73, 13.34 0.003
CI confidence interval, HAQ-DI Health Assessment Questionnaire-Disability
Index, HR hazard ratio, mRSS Modified Rodnan Skin Score, RP
Raynaud’s phenomenon
Table 4 Multivariable linear regression analysis of effect of
baseline characteristics on HAQ-DI score progression at 1 year
B 95% CI for B p value
Constant − 0.16 − 0.51, 0.20 0.389
HAQ-DI score at baseline − 0.15 − 0.27, − 0.04 0.009
Age at onset of RP − 0.002 − 0.01, 0.004 0.518
Male gender 0.02 − 0.18, 0.22 0.834
mRSS 0.01 0.0001, 0.03 0.048
Immunomodulator treatment 0.02 − 0.17, 0.20 0.870
Corticosteroids > 10 mg/day 0.12 − 0.77, 1.01 0.791
Advanced organ involvementa − 0.15 − 0.67, 0.37 0.575
Advanced lung involvement 0.05 − 0.55, 0.65 0.866
Advanced cardiac involvement 0.62 − 0.36, 1.60 0.213
Advanced GI involvementb 0.40 − 0.20, 0.99 0.186
Advanced renal involvement 0.47 − 0.56, 1.50 0.367
Esophageal symptoms 0.33 0.14, 0.52 0.001
Stomach symptoms − 0.04 − 0.25, 0.16 0.670
Intestinal symptoms 0.09 − 0.09, 0.26 0.335
CI confidence interval, GI gastrointestinal, HAQ-DI Health Assessment
Questionnaire-Disability Index, mRSS modified Rodnan Skin Score, RP
Raynaud’s phenomenon
aInvolved organs coded as 0 = none, 1 = one organ involvement, 2 = multiple
organ involvement
bMalabsorption or ≥ 10% weight loss from baseline
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worsening function (i.e., increasing HAQ-DI scores) over
1 year, whereas those with higher baseline HAQ-DI
scores showed improved functioning (i.e., decreasing
HAQ-DI scores). Major advanced organ involvement at
baseline was not predictive of HAQ-DI score progres-
sion at 1 year.
Transition model for dcSSc
The illustrative microsimulation model was run over
40 years (with a cycle length equal to 1 year) for a cohort
of patients with dcSSc experiencing HAQ-DI states tran-
sitions, developing advanced lung involvement, and
dying. The distribution of these patients over time be-
tween the various HAQ-DI, lung, and mortality states is
shown in Fig. 4. This prediction was based on a simu-
lated cohort of 1000 patients with the following baseline
characteristics: 33% male; aged 50 years; HAQ-DI score
< 0.5; no lung involvement; and time elapsed since dis-
ease onset equal to 0. dcSSc patients do not have a linear
HAQ-DI score evolution; therefore, a transition-based
model enabled a cohort of dcSSc patients to experience
both improvement and worsening of HAQ-DI score. By
modifying those baseline characteristics and simulating
another dcSSc population (e.g., all patients starting in
HAQ-DI score > 2.5), one can observe how patients are
differently distributed between the various health states
along the simulation (e.g., they will experience advanced
lung events faster and die sooner).
Discussion
The objectives of this EUSTAR database analysis were to
identify predictors of death (with an emphasis on HAQ-
DI score and major advanced organ involvement), to
identify predictors of HAQ-DI score progression at
1 year, and to develop a model to predict disease pro-
gression in dcSSc using HAQ-DI score, major advanced
organ involvement, and death rates. For death outcomes,
the study showed that baseline HAQ-DI score, cortico-
steroid treatment, and advanced major organ involve-
ment (1 or multiple organs) were predictive of death;
importantly, the study showed that baseline HAQ-DI
score and multiple major advanced organ involvement
were equally and independently predictive of death. The
link between corticosteroids and mortality risk is diffi-
cult to interpret, but they are commonly used for associ-
ated arthritis, myositis, or ILD, which all have poor
prognosis. Therefore, a bias for indication may apply;
corticosteroids > 10 mg/day could be a surrogate indica-
tor for more severe disease with a higher mortality risk.
For HAQ-DI score progression, patients with high
baseline mRSS and esophageal symptoms showed wors-
ening HAQ-DI score at 1 year, which may indicate that
these measures correlate well in assessing disease pro-
gression in patients with dcSSc. Patients with a high
baseline HAQ-DI score showed improved functioning,
which could be a regression to the mean or may reflect
a potential for improvement compared with those who
had low HAQ-DI scores at baseline.
A previous study of patients with SSc included in
the EUSTAR registry identified multiple predictors of
low survival, including male sex, age > 50 years, car-
diac impairment (LVEF < 50%), and ILD, although
HAQ-DI scores were not reported [20]. In the present
study, we can clearly see the importance of the HAQ-
DI score as a predictor of death in addition to these
predictors (notably major advanced organ involve-
ment); it is also a marker of disease progression that
may correlate well with mRSS. This is also consistent
with other studies where the HAQ was found to be
predictive of mortality in the general population and
in patients with rheumatoid arthritis and inflamma-
tory polyarthritis [21–23].
Fig. 4 Distribution of dcSSc patients over time between the various HAQ-DI, lung and mortality states as per an illustrative microsimulation that
was run over 40 years for a cohort of dcSSc patients. Note: Model was based on 1000 simulated patients with specific baseline characteristics
(33% male, age 50 years, HAQ-DI score < 0.5, no lung involvement, and known time since disease onset). dcSSc diffuse cutaneous systemic
sclerosis, HAQ-DI Health Assessment Questionnaire-Disability Index
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The clinical relevance of the findings from this study
is multi-fold. First, this analysis may change physician
perception about the HAQ-DI score, and they may now
rate it on a comparable level to more objective measures,
such as mRSS or organ involvement. Second, the HAQ-
DI score could be used as an endpoint in clinical studies
of patients with dcSSc. It has been used as an endpoint
in recent studies with tocilizumab [8] and abatacept [9]
in patients with SSc, and has been shown to be respon-
sive to treatment-induced changes in disease activity. In
one study, HAQ-DI score was used separately and as
part of the ACR Combined Response Index in Systemic
Sclerosis (ACR-CRISS, a composite endpoint that cap-
tures cardio-pulmonary-renal involvement and change
in mRSS, HAQ-DI score, patient and physician global
assessments, and FVC % predicted) [9]; this has been
used a primary outcome, and our findings support the
value of HAQ-DI score. Third, the HAQ-DI score
should be included in health technology assessments of
new drug treatments in dcSSc. Many self-evaluations in
clinical studies are now mandated by the US Food and
Drug Administration [9]. The HAQ-DI score has also
been supported in health technology appraisals by the
National Institute for Health and Clinical Excellence for
oral mycophenolate [24] and rituximab [25] in SSc. Fi-
nally, the transition model provides a useful way of mon-
itoring treatment needs over a lifetime horizon, and it
could be used in economic models to monitor the im-
pact of new treatments in different patient subgroups.
The strengths of this study include the use of a large,
prospective registry and rigorous documentation of
dcSSc and advanced organ involvement. In this model,
death rates were also calculated using an SMR. This is
the first time that SMRs per organ involvement have
been calculated, although it was not a key objective of
the study. The SMRs were higher than reported in previ-
ous studies [5, 26]. In one meta-analysis of 9 studies in
2691 patients with SSc, the pooled SMR was 3.53 (95%
CI 3.03, 4.11; p < 0.001). In another French study of 625
patients with SSc, overall SMR was 5.73 (95% CI 4.68,
6.94). Taken together, these studies highlight the devas-
tating nature of this condition.
Limitations include the observational design, lack of
treatment effect on outcomes, and no inclusion of non-
European patients. Regarding the computation of SMRs,
we observed a low number of deaths in each HAD-DI
category, and this resulted in a non-linear progression of
SMRs when increasing the HAQ-DI category. Therefore,
this low number of deaths in each of the five HAQ-DI
categories may introduce some instability in the results.
In addition, the model shown was a simplified illustra-
tion of how this tool could work to monitor disease pro-
gression. It did not account for any other organ
involvement, and only advanced lung involvement was
considered a predictor of death (HAQ-DI score is a pre-
dictor of death, along with some other baseline charac-
teristics, but these were not considered in order to avoid
multicollinearity issues). As SMRs were calculated exclu-
sively in dcSSc patients with non-missing HAQ-DI
values or non-missing lung status, it is likely SMRs for
dcSSc patients are slightly overestimated. Indeed, it is a
known fact that patient in critical condition are more
likely to have metabolic and questionnaire-related values
recorded. A meta-analysis (nine studies from 1960 to
2010) among SSc patients (not exclusively dcSSc pa-
tients) presented an SMR equal to 3.53 (95% CI 3.03,
4.11) [26]. This study also reported a non-significant
change of SMR over the past 40 years. Therefore, we
deemed the SMRs calculated among dcSSc patients as
acceptable.
Conclusions
This EUSTAR database analysis showed that HAQ-DI
scores offer a useful method of monitoring the natural
progression of dcSSc in relation to major advanced
organ involvement and death. The HAQ-DI score was
found to be a significant predictor of mortality risk, thus
highlighting the major importance of subjective mea-
sures on disease activity and patient well-being. It is
hoped that this could evoke a paradigm switch to focus-
ing on more global measures of disease activity in dcSSc,
and to rate the HAQ-DI scores in comparison to more
objective measures such as major advanced organ in-
volvement. Overall, these findings support the import-
ance of the HAQ-DI score as an endpoint in clinical
studies of therapeutic interventions in dcSSc. This ana-
lysis also provides a useful model for predicting long-
term disease progression in dcSSc.
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